Literature DB >> 21605981

The role of the GATA2 transcription factor in normal and malignant hematopoiesis.

Carmen Vicente1, Ana Conchillo, María A García-Sánchez, María D Odero.   

Abstract

Hematopoiesis involves an elaborate regulatory network of transcription factors that coordinates the expression of multiple downstream genes, and maintains homeostasis within the hematopoietic system through the accurate orchestration of cellular proliferation, differentiation and survival. As a result, defects in the expression levels or the activity of these transcription factors are intimately linked to hematopoietic disorders, including leukemia. The GATA family of nuclear regulatory proteins serves as a prototype for the action of lineage-restricted transcription factors. GATA1 and GATA2 are expressed principally in hematopoietic lineages, and have essential roles in the development of multiple hematopoietic cells, including erythrocytes and megakaryocytes. Moreover, GATA2 is crucial for the proliferation and maintenance of hematopoietic stem cells and multipotential progenitors. In this review, we summarize the current knowledge regarding the biological properties and functions of the GATA2 transcription factor in normal and malignant hematopoiesis. Copyright Â
© 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21605981     DOI: 10.1016/j.critrevonc.2011.04.007

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  72 in total

Review 1.  GATA2 deficiency.

Authors:  Amy P Hsu; Lisa J McReynolds; Steven M Holland
Journal:  Curr Opin Allergy Clin Immunol       Date:  2015-02

2.  DNA methylation shows genome-wide association of NFIX, RAPGEF2 and MSRB3 with gestational age at birth.

Authors:  Hwajin Lee; Andrew E Jaffe; Jason I Feinberg; Rakel Tryggvadottir; Shannon Brown; Carolina Montano; Martin J Aryee; Rafael A Irizarry; Julie Herbstman; Frank R Witter; Lynn R Goldman; Andrew P Feinberg; M Daniele Fallin
Journal:  Int J Epidemiol       Date:  2012-02       Impact factor: 7.196

3.  Sequencing of RNA in single cells reveals a distinct transcriptome signature of hematopoiesis in GATA2 deficiency.

Authors:  Zhijie Wu; Shouguo Gao; Carrie Diamond; Sachiko Kajigaya; Jinguo Chen; Rongye Shi; Cindy Palmer; Amy P Hsu; Katherine R Calvo; Dennis D Hickstein; Steven M Holland; Neal S Young
Journal:  Blood Adv       Date:  2020-06-23

Review 4.  A STATus report on DC development.

Authors:  Haiyan S Li; Stephanie S Watowich
Journal:  J Leukoc Biol       Date:  2012-05-01       Impact factor: 4.962

Review 5.  Erythro-megakaryocytic transcription factors associated with hereditary anemia.

Authors:  John D Crispino; Mitchell J Weiss
Journal:  Blood       Date:  2014-03-20       Impact factor: 22.113

Review 6.  Warts and all: human papillomavirus in primary immunodeficiencies.

Authors:  Jennifer W Leiding; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2012-10-01       Impact factor: 10.793

7.  Cooperative interaction of Etv2 and Gata2 regulates the development of endothelial and hematopoietic lineages.

Authors:  Xiaozhong Shi; Jai Richard; Katie M Zirbes; Wuming Gong; Gufa Lin; Michael Kyba; Jamie A Thomson; Naoko Koyano-Nakagawa; Daniel J Garry
Journal:  Dev Biol       Date:  2014-02-26       Impact factor: 3.582

8.  Megakaryocytes and platelets from a novel human adipose tissue-derived mesenchymal stem cell line.

Authors:  Keiichi Tozawa; Yukako Ono-Uruga; Masaki Yazawa; Taisuke Mori; Mitsuru Murata; Shinichiro Okamoto; Yasuo Ikeda; Yumiko Matsubara
Journal:  Blood       Date:  2018-11-28       Impact factor: 22.113

9.  Expression and prognostic significance of GATA-binding protein 2 in colorectal cancer.

Authors:  Lei Chen; Beihai Jiang; Zaozao Wang; Maoxing Liu; Yiyuan Ma; Hong Yang; Jiadi Xing; Chenghai Zhang; Zhendan Yao; Nan Zhang; Ming Cui; Xiangqian Su
Journal:  Med Oncol       Date:  2013-02-20       Impact factor: 3.064

10.  GATA2 is epigenetically repressed in human and mouse lung tumors and is not requisite for survival of KRAS mutant lung cancer.

Authors:  Mathewos Tessema; Christin M Yingling; Amanda M Snider; Kieu Do; Daniel E Juri; Maria A Picchi; Xiequn Zhang; Yushi Liu; Shuguang Leng; Carmen S Tellez; Steven A Belinsky
Journal:  J Thorac Oncol       Date:  2014-06       Impact factor: 15.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.